Principal Investigators
Leadership
Bernd Bodenmiller (ETH Zürich)
Bernd Bodenmiller is Dual Professor of Quantitative Biomedicine at ETH Zürich and University of Zurich and Director of the CCCZ Comprehensive Cancer Center Zurich Technologies. His lab develops experimental and computational methods to study tumor ecosystems on the single-cell level. The Bodenmiller group has pioneered a spatial mass spectrometric approach called imaging mass cytometry (IMC). It enables the simultaneous and spatially resolved quantification of approximately 50 markers on single cells and is used to investigate how cells in the tumor microenvironment drive cancer development and how they could be targeted for therapy.
Viola Heinzelmann-Schwarz (USB)
Viola Heinzelmann-Schwarz is Professor at University Hospital Basel, heading Gynecological Oncology and Gynecology and the Ovarian Cancer Research Group at the Department of Biomedicine of University of Basel. Her clinical and scientific focus is on gynecological carcinomas, especially ovarian carcinoma. Her research group combines basic, translational, and clinical approaches to identify biomarkers, to dissect mechanisms of metastasis and identify potential routes of precision medicine-driven therapeutic interventions.
Andreas Wicki (UZH)
Andreas Wicki is Professor of Oncology at University of Zurich, Vice Chairman of the Department of Oncology and Hematology at University Hospital Zurich and Director of the CCCZ Comprehensive Cancer Center Zurich clinical program. His area of expertise are molecular oncology, gastrointestinal oncology and neuroendocrine tumors. His research focuses on therapy prediction based on clinical and biological data (personalised oncology), early clinical trials and mechanisms of tumor invasion.
Principal Investigators
Niko Beerenwinkel (ETH Zürich)
Niko Beerenwinkel is Professor of Computational Biology at the Department of Biosystems Science and Engineering of ETH Zurich in Basel. His research is at the interface of mathematics, statistics, and computer science with biology and medicine. It includes statistical, evolutionary, and network modeling of molecular profiling data. He has developed several computational methods for supporting molecular diagnostics in oncology and virology, including for the analysis of tumor single-cell genomics data and of deep sequencing data obtained from virus populations.
Reinhard Dummer (UZH)
Reinhard Dummer is Professor of Dermatology at University of Zurich and Vice-Chairman of the Department of Dermatology at University Hospital of Zurich. His principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. Based on the microenvironment of these tumors, his research group has established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to patients to provide effective treatment with best quality of life.
Viktor Kölzer (USB)
Viktor Kölzer is Medical Co-Director of the Institute of Pathology and Full Professor of Experimental Pathology at the University Hospital of Basel. He is a board-certified pathologist and aims to improve patient care through application of new technologies to daily diagnostic practice and research. Previously he was an Attending Pathologist and Assistant Professor for Digital Pathology at the University and University Hospital of Zürich where he is now an associate faculty member. Prof. Kölzer holds an honorary position as senior clinical researcher at the University of Oxford. His research work has been recognized by national and international awards including the European Society of Pathology, the US and Canadian Academy of Pathology, the International Academy of Pathology, and the Scientist Award of the Siegenthaler Foundation.
Mitchell Levesque (UZH)
Mitch Levesque is Professor of Dermato-oncology at the University of Zurich. His laboratory is interested in applying molecular, cellular, and functional measurement technologies for understanding the mechanisms of melanoma progression and identifying novel biomarkers and drug targets. Specifically, his research group applies next-generation sequencing approaches and the latest omics tools to translational research questions to identify better predictive biomarkers for precision medicine as well as novel targets in late-stage melanoma.
Markus Manz (UZH)
Markus Manz is Professor of Hematology at University of Zurich, Director of the Department of Medical Oncology and Hematology at University Hospital Zurich and Chair of the CCCZ Comprehensive Cancer Center Zurich. His research is focused on hematopoietic and immune system development, homeostasis and function, as well as on hemato-lymphoid disease. His research group aims to gain basic knowledge and to provoke practical new strategies for clinical intervention in states of infection, immunodeficiency, autoimmunity, malignancy, and transplantation of hematopoietic cells.
Holger Moch (UZH)
Holger Moch is Professor of Pathology at University of Zurich, Director of the Institute of Pathology and Molecular Pathology at University Hospital Zurich and Director of the CCCZ Comprehensive Cancer Center Zurich Transversal Research Programs. He has developed a robust translational research program to understand the molecular background of solid tumors with a special interest in urogenital tumors. Using different molecular technologies and availability of large biorepositories with tumor tissue samples, his research group identified specific molecular alterations, which are important for better tumor diagnosis and improved understanding of tumor progression.
Lucas Pelkmans (UZH)
Lucas Pelkmans is Professor of Systems Biology at the Department of Molecular Life Sciences at University of Zurich. His research aims at conceptual problems and poorly understood phenomena and mechanisms by which biological scales are crossed, from single molecules to tissues. This research is applied at multiple levels, to understand how individual gene products, mRNA transcripts and proteins, are patterned within cells, form compartments, and give rise to variation in gene expression. The scientific vision and technological expertise of his research group is applied to the development of novel forms for post-genomics diagnostics, which aim at revealing scale-crossing effects in the emergence of disease phenotypes and responses to drugs.
Gunnar Rätsch (ETH Zürich)
Gunnar Rätsch is Professor of Biomedical Informatics in the Computer Science Department at ETH Zurich. He develops and applies advanced data analysis and modeling techniques to data from deep molecular profiling, medical and health records, as well as images. The group’s research interests range from algorithmic computer science to biomedical application areas. The group advances the state-of-the-art in data science algorithms, turns them into commonly usable tools for specific applications, and then collaborates with biologists and physicians on life science problems.
Berend Snijder (ETH Zürich)
Berend Snijder is Assistant Professor of Molecular Systems Biology at the ETH Zurich and interested in deciphering how cells work from a top-down point of view, focusing on the molecular networks and organizational principles that drive cellular behavior in health and disease. To pursue this question, his research group applies high-throughput automated microscopy, computer vision and machine learning, and integrative genomics and proteomics, to the systematic analysis of patient biopsies and various model systems. His research group is pioneering multiplexed image-based drug screening in patient tissues, a technique they call pharmacoscopy, to identify effective personal treatment options and better understand the molecular and cellular systems that determine how patients respond to their therapy.
Simone Münst Soysal (USB)
Simone Münst Soysal is an attending physician at the Institute of Pathology at the University Hospital Basel and associate professor in Pathology at Basel University, Switzerland. As a member of the Breast and Gynecological Tumor Center at the University Hospital Basel she is particularly interested in the molecular genetic analysis of neoplastic diseases, its role in prognosis and prediction as well as exploring new avenues of tumor characterization.
https://www.unispital-basel.ch/tumorzentrum/angebot/brustzentrum
Bernd Wollscheid (ETH Zürich)
Bernd Wollscheid is Professor at the Department of Health Sciences and Technology at ETH Zurich. The goal of his research is to functionally understand the cellular surfaceome and its signaling islands as a complex information gateway connecting the intracellular to the extracellular interactome. His research group develops and applies next generation technologies at the interface of biology, chemistry, medicine and bioinformatics to generate unprecedented data to establish the surfaceome proteotype and its signaling interaction network, which provides the basis to explain how molecular nanoscale organisation influences cellular signaling and biological function.
Supporting experts
Nora Toussaint (ETH Zürich)
Dr. Nora C. Toussaint leads the Biomedical Data Science group of NEXUS Personalized Health Technologies at ETH Zurich. She was the Data/IT workstream lead in the Tumor Profiler project and continues to be in charge of Data/IT for the Tumor Profiler Center. In this role she has been responsible for designing, implementing and maintaining the TuPro research data management system, enforcing standard operation procedures, and clinical reporting.